Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 5/20 | 0.61 |
| ▸ | LCK | P06239 | 3/20 | 0.46 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MECP2 | P51608 | 1/20 | 0.41 |
| ▸ | KCNN1 | Q92952 | 1/20 | 0.41 |
| ▸ | KCNN2 | Q9H2S1 | 1/20 | 0.41 |
| ▸ | MBD2 | Q9UBB5 | 1/20 | 0.41 |
| ▸ | KCNN3 | Q9UGI6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6180309 | 0.76 | KDR (1.00) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL15400995 | 0.75 | TNNI3K (0.39) | KDRMAPK10MEN1KMT2ANPC1 | |
| SCHEMBL29932950 | 0.73 | KDR (1.00) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL13701559 | 0.73 | KDR (1.00) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL2065572 | 0.73 | KDR (1.00) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL2868326 | 0.73 | KDR (0.65) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL1137510 | 0.73 | KDR (0.60) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL31039816 | 0.72 | LCK (0.63) | KDRLCKMAPK10MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL2861232 | 0.72 | KDR (0.63) | KDRLCKMAPK10MEN1KMT2A | |
| SCHEMBL4254787 | 0.72 | LCK (0.63) | KDRLCKMAPK10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9556202-B2 | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556202-B2 | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| US-9556202-B2 | Sulfonamide derivatives and methods of use thereof for improving the pharmacokinetics of a drug | MERCK SHARP & DOHME CORP. (US) | 2017-01-31 | — | — | US | disclosed |
| EP-2867220-B1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20150197531-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197531-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-07-16 | — | — | US | disclosed |
| US-20150197531-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2015-07-16 | — | — | US | disclosed |
| EP-2867220-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | Merck Sharp & Dohme Corp. (US) | 2015-05-06 | — | — | EP | disclosed |
| WO-2014000178-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2014-01-03 | — | — | WO | disclosed |
| WO-2014004416-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME CORP. (US) | 2014-01-03 | — | — | WO | disclosed |
| US-20140005103-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | MERCK SHARP & DOHME (US) | 2014-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150197531-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | SULT2A1, SULT1A1, SULT1E1 | KDR 1880/4885LCK 3511/4885MAPK10 4579/4885 |
| US-20140005103-A1 | SULFONAMIDE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG | SULT2A1, SULT1A1, SULT1E1 | KDR 1880/4885LCK 3511/4885MAPK10 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.